MX2014015287A - Derivado del ester del acido heteroarilcarboxilico. - Google Patents

Derivado del ester del acido heteroarilcarboxilico.

Info

Publication number
MX2014015287A
MX2014015287A MX2014015287A MX2014015287A MX2014015287A MX 2014015287 A MX2014015287 A MX 2014015287A MX 2014015287 A MX2014015287 A MX 2014015287A MX 2014015287 A MX2014015287 A MX 2014015287A MX 2014015287 A MX2014015287 A MX 2014015287A
Authority
MX
Mexico
Prior art keywords
acid ester
ester derivative
heteroarylcarboxylic acid
heteroarylcarboxylic
prophylactic
Prior art date
Application number
MX2014015287A
Other languages
English (en)
Inventor
Tadakiyo Nakagawa
Munetaka Tokumasu
Tatsuhiro Yamada
Takahiro Koshiba
Taisuke Ichimaru
Koji Ohsumi
Kayo Matsumoto
Tamotsu Suzuki
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of MX2014015287A publication Critical patent/MX2014015287A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/12—1,4-Dioxanes; Hydrogenated 1,4-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los compuestos representados por la siguiente fórmula (I); (ver Fórmula) en donde cada símbolo es definido en la especificación, son útiles como inhibidores hiperglucémicos con una acción inhibitoria de la serina proteasa y como fármacos profilácticos o terapéuticos para la diabetes.
MX2014015287A 2012-06-14 2013-06-14 Derivado del ester del acido heteroarilcarboxilico. MX2014015287A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/517,805 US9024044B2 (en) 2012-06-14 2012-06-14 Heteroarylcarboxylic acid ester derivative
PCT/JP2013/067015 WO2013187533A1 (en) 2012-06-14 2013-06-14 Heteroarylcarboxylic acid ester derivative

Publications (1)

Publication Number Publication Date
MX2014015287A true MX2014015287A (es) 2015-02-20

Family

ID=49756457

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015287A MX2014015287A (es) 2012-06-14 2013-06-14 Derivado del ester del acido heteroarilcarboxilico.

Country Status (8)

Country Link
US (3) US9024044B2 (es)
KR (1) KR102129716B1 (es)
AU (2) AU2013275197B2 (es)
BR (1) BR112014030966B1 (es)
CA (1) CA2876573C (es)
MX (1) MX2014015287A (es)
RU (1) RU2664544C2 (es)
WO (1) WO2013187533A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2511271B1 (en) 2009-12-07 2015-01-21 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
EP2725016B1 (en) 2011-06-07 2016-12-21 EA Pharma Co., Ltd. Heterocyclic carboxylic acid ester derivative
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
BR112015022762B1 (pt) 2013-03-13 2022-08-16 Takeda Pharmaceutical Company Limited Composto de éster do ácido guanidinobenzóico, composição farmacêutica, e, uso do composto
WO2014145561A2 (en) 2013-03-15 2014-09-18 Protagonist Therapeutics, Inc. Hepcidin analogues and uses therof
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
SG11201607558YA (en) * 2014-03-11 2016-10-28 Ea Pharma Co Ltd Method for producing heteroarylcarboxylic acid ester derivative, and production intermediate of same
SG11201607555SA (en) * 2014-03-11 2016-10-28 Ea Pharma Co Ltd Production method for heteroarylcarboxylic acid ester derivative, production intermediate thereof, and crystal
ES2890600T3 (es) 2014-05-16 2022-01-20 Protagonist Therapeutics Inc Péptidos de tioéter antagonistas de integrina alfa4beta7
KR102482790B1 (ko) 2014-07-17 2022-12-29 프로타고니스트 테라퓨틱스, 인코포레이티드 인터루킨-23 수용체의 경구용 펩티드 억제제 및 염증성 장 질환을 치료하기 위한 그의 용도
US9975903B2 (en) 2014-12-26 2018-05-22 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
KR102121647B1 (ko) 2015-01-15 2020-06-10 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 다능성 줄기세포로부터의 각막 상피 세포의 분화 유도 방법
US10017487B2 (en) 2015-03-27 2018-07-10 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CN105175392B (zh) * 2015-08-28 2019-04-19 湖南大学 一类含噻吩结构羧酸化合物和含噻吩结构酰胺化合物及其制备方法
CA3081564A1 (en) 2017-11-02 2019-05-09 Ube Industries, Ltd. Double-headed protease inhibitor
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
US20220281866A1 (en) 2019-07-19 2022-09-08 Janssen Pharmaceutica Nv 5,8-disubstituted-[1,2,4]triazolo[1,5-a]pyridinyl and 5,8-disubstituted-imidazo[1,2-a]pyridine derivatives useful as inhibitors of enteropeptidase
PL4038052T3 (pl) * 2019-10-02 2024-08-26 Domain Therapeutics Antagoniści receptora ep4 prostaglandyny e2 (pge2)
JOP20220169A1 (ar) 2020-01-15 2023-01-30 Janssen Biotech Inc مثبطات ببتيدية لمستقبلة انترلوكين-23 واستخدامها في معالجة الأمراض الالتهابية
WO2021146454A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021166899A1 (ja) * 2020-02-17 2021-08-26 宇部興産株式会社 インクレチン様物質と組み合わせて使用するための消化管プロテアーゼ阻害剤を含む薬剤
TW202214231A (zh) * 2020-08-19 2022-04-16 日商Ｅａ製藥股份有限公司 脂肪性肝疾病之治療劑
KR20230110570A (ko) 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. 인터류킨-23 수용체의 펩티드 억제제의 조성물
WO2022212698A1 (en) * 2021-04-01 2022-10-06 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6122075A (ja) 1984-07-10 1986-01-30 Torii Yakuhin Kk アミジン誘導体
US4563527A (en) 1984-07-19 1986-01-07 Torii & Co., Ltd. Amidine compounds
US5532267A (en) 1992-02-10 1996-07-02 Torii & Co., Ltd. Amidinonaphthyl furancarboxylate derivatives and acid addition salts therof
JPH05213927A (ja) 1992-02-10 1993-08-24 Torii Yakuhin Kk 新規フランカルボン酸アミジノナフチルエステル誘導体およびその酸付加塩
EP0703216B1 (en) 1994-09-20 1999-04-07 Ono Pharmaceutical Co., Ltd. Amidinophenol derivatives as protease inhibitors
JPH08143529A (ja) 1994-09-20 1996-06-04 Ono Pharmaceut Co Ltd アミジノフェノール誘導体、その製造方法、およびアミジノフェノール誘導体を有効成分として含有するロイコトリエンｂ４拮抗剤、ホスホリパーゼａ２および／またはトリプシン阻害剤
US6358960B1 (en) 1998-02-17 2002-03-19 Ono Pharmaceutical Co., Ltd. Amidino derivatives and drugs containing the same as the active ingredient
FR2783519B1 (fr) * 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US7671057B2 (en) 2004-11-08 2010-03-02 Ono Pharmaceutical Co., Ltd. Therapeutic agent for type II diabetes comprising protease-inhibiting compound
CA2588087A1 (en) 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S. Methods of reducing body fat
JP2008266174A (ja) 2007-04-18 2008-11-06 Kowa Co アミジノフェノール誘導体を有効成分とする糖化最終産物形成阻害剤
CA2707549A1 (en) 2007-12-03 2009-06-11 Itzik Harosh Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism
EP2511271B1 (en) 2009-12-07 2015-01-21 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
EP2725016B1 (en) 2011-06-07 2016-12-21 EA Pharma Co., Ltd. Heterocyclic carboxylic acid ester derivative
WO2013039187A1 (ja) 2011-09-15 2013-03-21 アステラス製薬株式会社 グアニジノ安息香酸化合物
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative

Also Published As

Publication number Publication date
US20130338132A1 (en) 2013-12-19
AU2017251698A1 (en) 2017-11-09
AU2013275197B2 (en) 2017-07-27
BR112014030966B1 (pt) 2022-07-05
CA2876573C (en) 2020-06-30
KR102129716B1 (ko) 2020-07-03
AU2013275197A1 (en) 2015-01-22
RU2664544C2 (ru) 2018-08-20
US9227949B2 (en) 2016-01-05
US9655879B2 (en) 2017-05-23
CA2876573A1 (en) 2013-12-19
BR112014030966A2 (pt) 2017-06-27
WO2013187533A1 (en) 2013-12-19
US20160058734A1 (en) 2016-03-03
KR20150023741A (ko) 2015-03-05
RU2015100901A (ru) 2016-08-10
US20150099733A1 (en) 2015-04-09
US9024044B2 (en) 2015-05-05

Similar Documents

Publication Publication Date Title
MX2014015287A (es) Derivado del ester del acido heteroarilcarboxilico.
UA110471C2 (ru) 5-алкінілпіримідини
TN2014000517A1 (en) Syringe
PH12015501083B1 (en) Novel pyridine derivatives
TN2013000347A1 (en) Production method of optically active dihydrobenzofuran derivative
MX343829B (es) N-ciclilamidas como nematicidas.
EA201591527A1 (ru) Новые производные пиридина
IN2015DN01035A (es)
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
IN2014MN01637A (es)
MX2013015308A (es) Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
WO2011143772A9 (en) Inhibitors of hiv replication
MX2014004920A (es) Nuevos derivados de pirazina.
AU2014230812A8 (en) Process for making benzoxazepin compounds
PH12015500877A1 (en) Flexible butadiene extraction process
EA201390336A1 (ru) Способ получения промежуточного соединения для синтеза лекарственного средства
IN2015DN02668A (es)
MX2014008918A (es) Nuevos derivados de pirrolidina.
MX342960B (es) Derivados de cromeno.
MX2015016766A (es) Nuevos derivados de tetrazolona.
GB2523674A (en) Compounds as inhibitor of DNA double-strand break repair, methods and applications thereof
WO2014008204A3 (en) Structures of proteasome inhibitors and methods for synthesizing and use thereof
NZ707087A (en) Novel flavonoid compounds and uses thereof
LT2012082A (lt) Nauji fotochrominiai junginiai, jų gamybos būdas ir tarpiniai junginiai jiems gauti
PH12015500262A1 (en) Novel pyridine derivatives

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: EA PHARMA CO., LTD.

FG Grant or registration